Analyst consensus rating
CRISPR Therapeutics Analyst Rating: Buy
CRSP is rated Buy by 18 analysts with a $87.56 target. As of 2026-09-02.
Direct answer
CRISPR Therapeutics's consensus rating is Buy.
18 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $87.56.
Forecast evidence checked September 2, 2026.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $56.82
- Average price target
- $87.56
- High price target
- $291.00
- Low price target
- $44.00
- Low target gap
- -22.6%
- Target upside
- +54.1%
- High target gap
- +412.1%
- Target range width
- 434.7%
- Consensus rating
- Buy
- Analysts
- 18
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for CRISPR Therapeutics?
CRISPR Therapeutics has a verified Buy consensus. The same dataset has an average price target of $87.56.
How far are CRISPR Therapeutics's low and high targets from the recorded price?
The low target implies -22.6%, while the high target implies +412.1%.
How many analysts are included in CRISPR Therapeutics's consensus?
The verified consensus includes 18 analysts.
How is CRISPR Therapeutics's target upside or downside calculated?
The average target of $87.56 is divided by the recorded price of $56.82, then one is subtracted to produce +54.1%. This does not guarantee a future return.
When was CRISPR Therapeutics's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.